Nikolai Strusberg, MD, discussed how proton therapy and thyroid dose affect clinical hypothyroidism risk after supraclavicular breast radiation.
|Poll|April 28, 2014
Extremely Pruritic Skin on 52-Year-Old Patient
Author(s)Andra Krauze, BSc, MD, FRCPC
A 52-year-old male presents with a 3-month history of extremely pruritic skin on the wrist and hand. On exam the patient exhibits generalized erythroderma and lymphadenopathy. What is the diagnosis?
Advertisement
A 52-year-old male presents with a 3-month history of extremely pruritic skin on the wrist and hand. On exam the patient exhibits generalized erythroderma and lymphadenopathy. Peripheral blood smear is performed.
The diagnosis is:
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, compared MRD data with Tec-Dara and Tal-Dara and explained how sustained MRD negativity is reshaping myeloma care.
Alexandra Dreyfuss, MD, MS, weighs bridging vs consolidative radiotherapy strategies around CAR T-cell infusion in myeloma.
In a phase 1 trial of patients with platinum-sensitive high-grade ovarian cancer, a personalized neoantigen vaccine plus nivolumab caused no unexpected safety signals.
The new guidelines include 10 recommendations spanning extended molecular testing, JAK inhibitor use, anemia management, and other areas in myelofibrosis.
Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose antidepressant.
Heath Skinner, MD, PhD, discussed the 4 focus areas of the 2026 Radiation Oncology Conference and what it takes to implement new radiation service lines.
The FDA has assigned a Prescription Drug User Fee Act date of March 31, 2027, for tabelecleucel in this indication.
Advertisement
Advertisement
Trending on CancerNetwork
1
VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors
2
Reading a Changed Eye Examination and Impact on Therapy
3
Personalized Cancer Vaccine Combo Is Feasible in Platinum-Sensitive Ovarian Cancer
4
FDA Expands Approval for Nogapendekin Alfa in BCG-Unresponsive NMIBC
5